Multidisciplinary Management of Fabry Disease: Current Perspectives.
Luciana Paim-MarquesRodrigo Joel de OliveiraSimone AppenzellerPublished in: Journal of multidisciplinary healthcare (2022)
Fabry disease (FD) is a rare, recessive X-linked, multisystemic lysosomal storage disorder (LSD) that results from a deficiency in the hydrolase alpha-galactosidase A (α-GalA) caused by a GLA gene variant. The progressive accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in organs such as skin, kidney, brain, joints, vascular walls and eyes are responsible for the wide spectrum of clinical manifestations, often unspecific. In result, clinically relevant and life-threatening complications, such as malignant ventricular arrhythmia, sudden cardiac death, end stage kidney failure and stroke may occur. In this review, we will describe the clinical features and the current perspectives in the multidisciplinary management Of FD patients.
Keyphrases
- replacement therapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- heart failure
- multiple sclerosis
- atrial fibrillation
- peritoneal dialysis
- left ventricular
- catheter ablation
- prognostic factors
- risk factors
- optical coherence tomography
- intellectual disability
- gene expression
- white matter
- cerebral ischemia
- autism spectrum disorder
- genome wide identification